8-K: Immunocore Reports Strong Q1 2025 Financial Results with KIMMTRAK Sales Driving Growth

Immunocore announces a 33% year-over-year increase in KIMMTRAK net revenues, reaching $93.9 million in Q1 2025, and provides updates on its clinical pipeline.

Summary

• Immunocore Holdings plc reported its financial results for the first quarter ended March 31, 2025.
• KIMMTRAK net revenues reached $93.9 million, a 33% increase compared to Q1 2024.
• The company is on track to complete enrollment for the Phase 3 TEBE-AM trial in the first half of 2026.
• Dose selection for the Phase 3 PRISM-MEL-301 trial is expected in the second half of 2025.
• Initial data for the HIV functional cure candidate was presented at CROI 2025, with dose escalation ongoing.
• As of March 31, 2025, Immunocore had $837 million in cash, cash equivalents, and marketable securities.
• Net income for the first quarter of 2025 was $5.0 million, compared to a net loss of $24.4 million in the same period in 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, a transition to net income, and progress in clinical trials. The company's strong cash position further supports a positive sentiment.

Positives

• Significant revenue growth for KIMMTRAK, with a 33% increase year-over-year.
• The company achieved net income in Q1 2025, a turnaround from the net loss in the same period last year.
• Strong cash position with $837 million in cash, cash equivalents, and marketable securities.
• Advancement of multiple clinical programs, including Phase 3 trials for TEBE-AM and PRISM-MEL-301.
• Positive initial data from the HIV trial, indicating potential for viral control.

Risks

• The document mentions forward-looking statements are subject to risks and uncertainties that could cause actual events or results to differ materially.
• These risks include the impact of worsening macroeconomic conditions, ability to obtain clinical and commercial supply, regulatory approval, competition, unexpected safety or efficacy data, actions of regulatory agencies, need for additional funding, intellectual property protection, and the success of collaborations.

Future Outlook

The company anticipates continued growth in KIMMTRAK sales through global expansion and potential label expansions. Immunocore also expects to advance its clinical pipeline, with key milestones including completing enrollment for the TEBE-AM trial and selecting a dose for the PRISM-MEL-301 trial.

Management Comments

• Bahija Jallal, Chief Executive Officer of Immunocore, stated, 'We are thrilled to have achieved strong revenue performance in Q1, marked by year-over-year growth of 33%.'
• Bahija Jallal also noted, 'In R&D, we continue to be laser-focused on execution in our oncology franchise with three ongoing Phase 3 trials and a promising early pipeline.'

Industry Context

Immunocore is operating in the competitive fields of oncology, infectious diseases, and autoimmune diseases. The company's KIMMTRAK is a novel therapy for uveal melanoma, a rare and aggressive cancer. The company is also developing ImmTAC molecules for other cancers, HIV, hepatitis B, type 1 diabetes, and atopic dermatitis.

Comparison to Industry Standards

• KIMMTRAK's performance can be compared to other targeted therapies in melanoma, such as checkpoint inhibitors (e.g., pembrolizumab, nivolumab) and BRAF inhibitors (e.g., vemurafenib, dabrafenib).
• The company's HIV program can be compared to other companies working on HIV cure strategies, such as Gilead Sciences and ViiV Healthcare.
• The company's autoimmune disease programs can be compared to other companies developing therapies for type 1 diabetes and atopic dermatitis, such as Eli Lilly and Sanofi.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and clinical progress.
• Patients may benefit from the continued development and potential approval of new therapies.
• Employees may be motivated by the company's success and growth prospects.

Next Steps

• Complete enrollment in the Phase 3 TEBE-AM trial in the first half of 2026.
• Select the go-forward brenetafusp dose in the second half of 2025 for the PRISM-MEL-301 trial.
• Report data from the single ascending dose portion of the IMC-I109V (Envelope-A02) trial in the second half of 2025.
• File a CTA or IND for IMC-S118AI (PPI x PD1) in the second half of 2025.
• File a CTA/IND for IMC-U120AI (CD1a x PD1) in 2026.

Key Dates

Keywords

KIMMTRAK, Immunocore, uveal melanoma, cutaneous melanoma, clinical trials, financial results, ImmTAC, oncology, HIV, autoimmune diseases